Quince Therapeutics S.p.A.

Quince Therapeutics S.p.A. focuses its clinical research on Ataxia Telangiectasia and the associated neurological burden of this rare genetic disorder, with particular attention to central nervous system symptoms and functional impairment in children.

• CNS symptoms
• Neurological dysfunction
• Rare disease care

The sponsor’s research activity in this area is directed toward understanding and addressing the motor and neurological manifestations of Ataxia Telangiectasia.